UniQure: Funding, Investors & Team (Sep 2026)
uniQure is a leader in the field of gene therapy and had developed the first and currently the only gene therapy product to receive regulatory approval in the European Union. Gene therapy offers the prospect of long-term and potentially curative benefit to patients with genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration. Our first product, Glybera, was approved by the European Commission in October 2012 under exceptional circumstances for the treatment of a subset of patients with lipoprotein lipase deficiency, or LPLD, a potentially life-threatening, orphan metabolic disease. We are also developing a pipeline of additional adeno-associated virus (AAV)-based gene therapies through multiple collaborations. We develop our gene therapies using our innovative, modular technology platform, including our proprietary manufacturing process. We initially are focused on orphan diseases but believe that we will also be able to develop gene therapies targeting chronic and degenerative diseases that affect larger populations.
UniQure has raised $259M across 1 funding round on record, the most recent an undisclosed round of $259M announced in Jun 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
UniQure Company Profile and Key Stats
Latest funding round on record: Jun 2026.
UniQure Funding Rounds
UniQure Founders and Leadership Team
No contact details are on record for this team yet.
UniQure Funding Compared to Other Biotechnology Startups
UniQure's latest round of $259M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like UniQure in Biotechnology and Amsterdam
Companies Similar to UniQure
ProQR Therapeutics is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients…
Vertoro transforms woody and agricultural residues into a wide range of bio-based chemicals, materials, and…
Vivici is a B2B ingredients firm that provides nutritious and sustainable animal-free dairy proteins…
New Dawn Bio is a biotechnology research firm that specializes in wood production.
Triple Bio is a biotech startup focused on improving productivity and sustainability in dairy and beef…
Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and…
ATRO Medical is a spin-out from DSM and Radboudumc and builds on the knowledge developed in the…
Detact holds the patent for a new, innovative, real-time, bacterial detection system that enables hospital…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
MAASH is a biotech mycoprotein producing company that supply a nutritious and health feed and food protein…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
UniQure Funding FAQs
What does UniQure do?
uniQure is a leader in the field of gene therapy and had developed the first and currently the only gene therapy product to receive regulatory approval in the European Union. Gene therapy offers the prospect of long-term and potentially curative benefit to patients with genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration. Our first product, Glybera, was approved by the European Commission in October 2012 under exceptional circumstances for the treatment of a subset of patients with lipoprotein lipase deficiency, or LPLD, a potentially life-threatening, orphan metabolic disease. We are also developing a pipeline of additional adeno-associated virus (AAV)-based gene therapies through multiple collaborations. We develop our gene therapies using our innovative, modular technology platform, including our proprietary manufacturing process. We initially are focused on orphan diseases but believe that we will also be able to develop gene therapies targeting chronic and degenerative diseases that affect larger populations.
How much funding has UniQure raised?
UniQure has raised $259M across 1 round on record. The most recent is an undisclosed round of $259M announced in Jun 2026.
When did UniQure last raise funding?
UniQure's most recent funding round on record is an undisclosed round of $259M, announced in Jun 2026.
Who founded UniQure?
FundedIQ lists Matthew Kapusta (Founder) at UniQure.
Where is UniQure headquartered?
UniQure is based in Amsterdam, Noord-Holland, The Netherlands.
How many employees does UniQure have?
UniQure is in the 101-250 employee band.
How does UniQure's funding compare to other Biotechnology startups?
UniQure's latest round of $259M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's UniQure Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for UniQure is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.